New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.
Published this week in the journal Molecular Cancer Research, Cramer’s study specifically looks at how the loss of two specific prostate tumor-suppressing genes — MAP3K7 and CHD1 –increases androgen receptor signaling and makes the patient more resistant to the anti-androgen therapy that is typically administered to reduce testosterone levels in prostate cancer patients.